drugset / Trial / NCT05963048
Rituxmab Versus IL-6 in Treating ILD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-12-30
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 6 mg/kg | Intravenous |